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Idiopathic cytopenias are frequently observed in patients after allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). We have previously reported the effect of graft-versus-host disease (GVHD) on bone
marrow (BM) in murine models, indicating that the osteoblast injury mediated by donor T cells was asso-
ciated with bone marrow suppression and delayed immune reconstitution. In this study, we prospectively
evaluated the relevance of these ﬁndings in 51 patients. Patients with chronic GVHD manifested the loss of
osteoblasts, contributing to cytopenic symptoms (P ¼ .0427 compared with patients without cytopenic
symptoms). The loss of osteoblasts was signiﬁcantly associated with the extensive type of chronic GVHD
(P ¼ .012), and ﬂow cytometric analyses revealed lower numbers of CD19þ B cells and a signiﬁcantly increased
CD4 to CD8 ratio (P ¼ .0002) in these patients. Our data, for the ﬁrst time to our knowledge, summarize the
detailed analyses of the effect of GVHD on BM in the clinical allo-HSCT patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION in BM suppression, including B lymphopoiesis. We identiﬁed
Allogeneic stem cell transplantation (allo-HSCT) is
currently established as a curative therapy for hematologic
malignancies. However, graft-versus-host disease (GVHD)
still remains a major complication after allo-HSCT and,
therefore, developing better strategies for the prophylaxis
and treatment of GVHD is essential to improve outcomes of
allo-HSCT. The principal target organs of acute GVHD are the
skin, liver, and gastrointestinal tract [1]. However, cytopenias
and bone marrow (BM) suppression are often observed in
association with GVHD in patients undergoing allo-HSCT,
suggesting that BM is a potential target of GVHD. Clinical
and experimental data have shown that immunologic
reconstitution is impaired by GVHD [2-5], and GVHD-
associated myelosuppression and lymphoid hypoplasia
have been reported [6-8]. Recently, we demonstrated the
destruction of BM hematopoietic niches, especially osteo-
blasts, by donor T cells in murine models of GVHD, resultingdgments on page 499.
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13.12.568this phenomenon as BM GVHD [9]. Here, we report clinical
research investigating BM GVHD in patients after allo-HSCT.
We analyzed 51 patients undergoing allo-HSCT who were
evaluable with BM biopsy samples both before and after allo-
HSCT.
METHODS
Study Design and Patients
For our prospective analyses of BM GVHD, we enrolled 57 patients who
underwent allo-HSCT from February 2010 to June 2012 in Hokkaido Uni-
versity Hospital. A total of 51 patients were assessed for BM biopsy speci-
mens before and after allo-HSCT (6 patients who did not have BM biopsies at
all after allo-HSCT were excluded). The study protocol was approved by the
review board of Hokkaido University Graduate School of Medicine on
January 29, 2010. Patients provided written informed consent before being
enrolled in the protocol. Characteristics of patients, as well as of the trans-
plantation procedures, are summarized in Table 1.
Evaluation of GVHD
Diagnosis and clinical grading of acute and chronic GVHD were
performed according to established criteria [10-12].
Bone Marrow Samples
We performed BM biopsies and aspirations for patients before and after
allo-HSCT. BM aspirates were analyzed for B and T cell proﬁles by ﬂow
cytometry. Biopsied specimens were stained with hematoxylin and eosin, as
well as with CD56 for immunohistochemical assessments of cellularity,
morphology, and presence or absence of osteoblasts [13]. We categorized
the loss of osteoblasts into 3 groups: (1) not affected, if the osteoblasts were
intact or the decrease was moderate, up to 30%; (2) partial loss, if theTransplantation.
Table 1
Characteristics of Patients
Characteristics Value
No. of transplantations 51
Age, median (range), yr 41 (19-66)
Patient sex
Male 27 (53%)
Female 24 (47%)
Disease
AML 16 (31%)
MDS 5 (10%)
ALL/LBL 12 (24%)
ML 9 (18%)
ATL 3 (6%)
AA 3 (6%)
Others 3 (6%)
Donor sources
U-BMT 28 (55%)
R-PBSCT 8 (16%)
R-BMT 5 (10%)
CBT 10 (20%)
Preparative regimen
CST 20 (39%)
RIST 31 (61%)
Immuno suppression
CyA based 13 (25%)
FK based 38 (75%)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; ALL/LBL, acute lymphocytic/lymphoblastic lymphoma; ML, malig-
nant lymphoma; ATL, acute T cell leukemia; AA, aplastic anemia; U-BMT,
unrelated bone marrow transplantation; R-PBSCT, related peripheral blood
stem cell transplantation; R-BMT, related bone marrow transplantation;
CBT, cord blood transplantation; CST, conventional stem cell trans-
plantation; RIST, reduced-intensity stem cell transplantation; CyA, cyclo-
sporin A; FK, tacrolimus.
Data presented are n (%) unless otherwise indicated.
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in the pathological sections; and (3) complete loss, if more than 90% of os-
teoblasts were lost.
Assessment of Cytopenias
We identiﬁed the cytopenic condition as idiopathic cytopenias after
excluding the following conditions. We excluded bacterial, fungal, and viral
infections by routine screening tests (serological as well as culture tests).
Additionally, thrombo microangiopathy and hemophagocytic syndrome
that also cause cytopenias in patients were excluded. Insufﬁcient hemato-
poiesis after engraftment was also excluded when the patient showed
recovery (conﬁrmed retrospectively) in hematopoiesis without any speciﬁc
treatment for the cytopenias.
Statistical Analysis
Median values and ranges were used for continuous variables and per-
centages were used for categorical variables (Table 1). Gray’s test was used
for group comparisons of cumulative incidences of acute and chronic GVHD.
Statistical analyses were performed using chi-square test and t-test, asFigure 1. Cumulative incidences of acute (A) and chronic (B) GVHappropriate. JMP software version 8.0.2 (SAS Institute, Cary, NC) was used
for most of the statistical analyses. Analysis of cumulative incidences was
carried out with EZR (Saitama Medical Center, Jichi Medical University,
http://www.jichi.ac.jp/saitama-sct/SaitamaHP.ﬁles/statmedEN.html), which
is a graphical user interface for R (The R Foundation for Statistical
Computing, version 2.13.0) [14]. All P values were 2 sided and a value of
P ¼ .05 was used as a cut off for statistical signiﬁcance.
RESULTS
Patients’ Characteristics, Sample Collections, and Acute
and Chronic GVHD after Allo-HSCT
The patients’ characteristics are shown in Table 1. The
median age at allo-HSCT for the 27males and 24 females was
41 years (range, 19 to 66). Of 51 patients analyzed, 32
developed acute GVHD (Figure 1A) and 29 developed chronic
GVHD (Figure 1B). BM biopsies were performed before
(median, day 22; range, day 174 to day 8) and after
(median, day 63; range, day 18 to day 527) allo-HSCT
together with BM aspirations. The average number of the
BM biopsies performed after allo-HSCT was 1.7 per patient
(range, 1 to 6). We found a signiﬁcant decrease of BM cellu-
larity in samples collected from patients suffering from
cytopenias in the peripheral blood (Supplemental Table 1).
The characteristics of GVHD, in terms of the duration from its
onset to BM biopsy, as well as the percentage of donor
chimerism in the samples with cytopenic symptoms are
shown in Supplemental Table 2.
BM GVHD and BM Suppression during Acute GVHD
We analyzed a total of 56 BM samples biopsied from day
0 to day 100 after allo-HSCT (Figure 2). Of these 56 samples,
15 were harvested when the patients had acute GVHD. Eight
of these 15 samples were harvested from patients suffering
from cytopenias and 2 of them displayed partial loss of os-
teoblasts, identifying 1 sample as an idiopathic cytopenia.
We also identiﬁed 3 samples presenting the partial loss of
osteoblasts; however, none of these 3 samples were collected
when patients showed clinical manifestation of acute GVHD
symptoms. The causes of cytopenias for these 3 samples
included disease relapse and delayed engraftment. Taken
together, during the early period after allo-HSCT, we did not
observe a strong correlation between loss of osteoblasts and
idiopathic cytopenias.
BM GVHD and BM Suppression during Chronic GVHD
We analyzed a total of 33 samples biopsied beyond day
100 (Figure 3A). Of 14 samples harvested from patients when
they exhibited symptoms of chronic GVHD and concurrent
idiopathic cytopenias, 4 samples displayed partial loss ofD after allogeneic hematopoietic stem cell transplantation.
Figure 2. Assessments of bone marrow biopsy samples from patients up to
day 100 after allogeneic hematopoietic stem cell transplantation. aGVHD in-
dicates acute graft-versus-host disease; Bx, biopsy.
Table 2
Loss of Osteoblasts and Its Correlation with Chronic GVHD in BM Samples
after Day 100
Chronic GVHD Loss of
Osteoblasts (þ)
(n ¼ 14 Samples)
Loss of
Osteoblasts ()
(n ¼ 19 Samples)
P Value
Any chronic GVHD 11 8 .0324
Limited chronic GVHD 3 5 .7451
Extensive chronic GVHD 8 3 .0120
GVHD indicates graft-versus-host disease; BM, bone marrow.
Bold values indicate 2-tailed chi-square test.
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osteoblasts. We further detailed the types of chronic GVHD
affecting these idiopathic cytopenias and found 10 of 19
samples from patients suffering from idiopathic cytopenias
displayed extensive chronic GVHD (Figure 3B). The loss of
osteoblasts was signiﬁcantly correlated with the extensive
type of chronic GVHD (Table 2, P ¼ .012) and also with
idiopathic cytopenias in patients with chronic GVHD
(Table 3, P ¼ .0427). Among samples collected when patients
had no cytopenic symptoms, no loss of osteoblasts were
observed. We observed a signiﬁcantly higher frequency of
GVHD treatment with steroids in patients with osteoblast
loss during chronic GVHD (Table 4). Characteristic patho-
logical analyses of these cases, as well as a control BM sam-
ple, are summarized below.
Case 1: A patient with no GVHD and no cytopenias
Figure 4A indicates a pathological sample from a 47-year-
old female who had no episodes of GVHD symptoms and no
cytopenias when her BM sample was harvested on day 41. In
hematoxylin and eosin staining, osteoblasts lining bone
trabeculae are well observed before allo-HSCT and on day 41
(arrowheads). The lower panels showCD56 staining from theFigure 3. Assessments of bone marrow biopsy samples from patients after day
100 after allogeneic hematopoietic stem cell transplantation. (A) Relations
between loss of osteoblasts and idiopathic cytopenias. (B) Grades of chronic
GVHD and their relations to idiopathic cytopenias.same patient. Previous reports indicate neural cell adhesion
molecule (NCAM, CD56) is strongly expressed by human
osteoblasts [13]; therefore, we used CD56 staining for our
samples to speciﬁcally identify osteoblasts.
Case 2: A patient with chronic liver and skin GVHD with
cytopenias
A 57-year-old male patient underwent allo-HSCT from an
HLA identical sibling. His underlining disease (anaplastic
large cell lymphoma) relapsed on day 134 and tacrolimus
was tapered off afterwards. Chronic extensive GVHD of the
liver manifested on day 168, followed by deterioration of
cutaneous and oral chronic GVHD and cytopenias, including
platelets and red blood cells (grade 4 in platelets and grade 2
in hemoglobin by Common Terminology Criteria for Adverse
Events version 4). BM biopsy on day 176 shows the complete
loss of osteoblasts (Figure 4B). Chronic GVHD and cytopenias
were then improved by the resumption of low-dose tacroli-
mus, and BM biopsy on day 521 showed recovery of
osteoblasts.
Case 3: A patient with sustained cytopenias with skin GVHD
Figure 4C shows BM from a 37-year-old male patient
receiving allo-HSCT from an HLA mismatched unrelated
donor. Gradual cytopenias was observed from day 90 after
allo-HSCT with stage 1 cutaneous GVHD. BM biopsy on day
127 displays complete loss of osteoblasts. When he recov-
ered from these symptoms, osteoblasts reappeared on the
sample taken on day 260.
Case 4: A patient with gradual loss of osteoblasts with
worsening GVHD
A 27-year-old male patient underwent allo-HSCT from an
unrelated donor. He achieved neutrophil engraftment on day
20; however, he remained dependent on platelet and red
blood cell transfusions. He developed stage 1 skin GVHD on
day 34. Red blood cell and platelet engraftment wereTable 3
Loss of Osteoblasts and its Correlation with Idiopathic Cytopenias in BM
Samples after Day 100
Loss of
Osteoblasts*
cGVHD (þ),
Idiopathic
Cytopenia (þ)
(n ¼ 14 Samples)
cGVHD (þ),
Idiopathic
Cytopenia ()
(n ¼ 5 Samples)y
P Value
Any osteoblast loss 10 1 .0427
Partial loss 4 1 .7032
Complete loss 6 0 .0324
BM indicates bone marrow; cGVHD, chronic graft-versus-host disease.
Bold values indicate 2-tailed chi-square test.
* Loss of osteoblasts is deﬁned as partial if loss of osteoblasts is observed
in 30% to 90% of the bone trabeculae in the pathological sections and com-
plete if more than 90% of the osteoblast are lost.
y These samples include n¼ 3 samples without cytopenias and n¼ 2 with
cytopenias with identiﬁed causes.
Table 4
Steroid Administration and Loss of Osteoblasts in Chronic GVHD BM Sam-
ples after Day 100
Steroid
Therapy at
BM Biopsy
Loss of Osteoblasts (þ)
cGVHD (þ)
(n ¼ 11 Samples)
Loss of Osteoblasts ()
cGVHD (þ)
(n ¼ 8 Samples)
P Value
(þ) 8 2 .0360
() 3 6
GVHD indicates graft-versus-host disease; BM, bone marrow; cGVHD;
chronic graft-versus-host disease.
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(>20,000/mL), respectively. Osteoblasts were partially lost on
BM samples taken on day 36 (Figure 4D). Cytopenias
continued, and he then developed chronic lung GVHD
exacerbating from day 97, which was successfully treated
with steroid therapy. However, the cytopenias persisted
and the complete loss of osteoblasts was observed in BM
samples taken on day 147. These results demonstrate the
potential correlation between systemic (and supposedly
affecting BM) GVHD and loss of BM osteoblasts leading to
cytopenias. The patient did not develop bronchiolitis oblit-
erans syndrome.Figure 4. Loss of osteoblasts during GVHD and cytopenias. Biopsied bone marrow (
pictures), as well as with CD56 (lower panels for all pictures) for assessments of cellula
images is 400. (A) BM samples from a 47-year-old patient after unrelated bone ma
biopsies were performed. Osteoblasts are well preserved. Arrowheads indicate osteob
cell transplantation and relapsed on day 134 developed symptoms of chronic GVHD a
and when he recovered from those symptoms osteoblasts are back on day 521. (C)
gradually developed cytopenias after day 90 with stage 1 skin GVHD. The BM sampl
subsided, osteoblasts recovered to a normal level. (D) A 27-year-old patient who und
blood cells on day 20; however, cytopenias had persisted and he developed stage 1 sk
68 and he had been on high demand of red blood cell and platelet transfusions. TheSuppression of CD19þ B Cells and Increased CD4 to CD8
Ratio in BM Samples with the Loss of Osteoblasts
We next examined the BM aspirates samples taken at the
same time points of the BM biopsies. We analyzed samples
collected after day 100 by categorizing them into 3 sub-
groups based on the status of osteoblasts: not affected, par-
tial loss, and complete loss. We observed decreased numbers
of CD19þ B cells and CD3þ T cells in parallel with the loss of
osteoblasts (Figure 5). Also, we found the ratio of CD4 and
CD8 T cells was signiﬁcantly increased with the loss of os-
teoblasts (P ¼ .0002, not affected versus complete loss).
These data indicate the effects of BM GVHD, resulting in
disrupted hematopoiesis after allo-HSCT and are consistent
with our mouse model data in the setting of BM GVHD [9].
DISCUSSION
In the settings of clinical allo-HSCT, patients frequently
suffer from sustained cytopenias that parallel systemic
GVHD. Some patients in the outpatient clinics after day 100
develop cytopenias without any signs of infection or GVHD.
The causes for these cytopenias include relapse of original
disease, viral (or bacterial) infections, and/or side effects of
drugs, and it is very important to identify the cause as it
directly affects the treatment decision for these patients. ByBM) samples were stained with hematoxylin and eosin (upper panels for all
rity, morphology, and presence or absence of osteoblasts. Magniﬁcation for the
rrow transplantation who had no episode of GVHD and cytopenias when BM
lasts. (B) A 57-year-old patient who underwent related peripheral blood stem
nd cytopenias after day 160. Complete loss of osteoblasts is shown on day 176,
A 37-year-old patient after related peripheral blood stem cell transplantation
es on day 127 show clear loss of osteoblasts. On day 260, when his symptoms
erwent unrelated bone marrow transplantation attained engraftment of white
in GVHD on day 34. Partial loss of osteoblasts was observed from day 36 to day
BM samples on day 147 indicate complete loss of osteoblasts.
Figure 5. Flow cytometric analyses of BM aspirates in patients after day 100. BM aspiration was performed at the same time of BM biopsy in these patients.
Cellularity, nucleated cell count (NCC), CD19þ cells, CD3þ cells, and the ratio of CD4þ to CD8þ cells are shown.
Y. Shono et al. / Biol Blood Marrow Transplant 20 (2014) 495e500 499evaluating BM biopsy samples with hematoxylin and eosin,
as well as CD56 immunohistochemical staining, we analyzed
BM osteoblasts and compared these results with the
respective clinical courses. As a result, we conﬁrmed the
disappearance of osteoblasts in samples from patients with
idiopathic cytopenias and chronic GVHD during the late
stage after allo-HSCT, suggesting the correlation between
chronic GVHD and BM GVHD, resulting in BM suppression.
Bone damage after allo-HSCT [15], especially suppression of
B lymphopoiesis during GVHD, has been reported in both
clinical and experimental studies [2,6,16-19], and our previ-
ous study in murine models unveiled new details of the
mechanisms involved in this phenomenon, focusing on the
destruction of hematopoietic niches by donor T cells in the
course of GVHD [9]. In this article, we also reported the an-
alyses of various clinical factors in BM, including cellularities
and B cell analyses, which indicated the correlation with BM
GVHD in human chronic GVHD cases. Consistent with our
ﬁndings in murine GVHD models, we observed a decreased
number of CD19þ B cells and an increased CD4 to CD8 ratio in
patients with osteoblast destruction; however, these ﬁnd-
ings were not observed during the early period after allo-
HSCT, when in the murine models, donor CD4þ T cells
mediated strong BM GVHD. It is possible that in the clinical
settings, patients are treated with immunosuppressive
therapy and this could have prevented acute BM GVHD
[20,21]. In cases of patients treated with steroids, it is quite
difﬁcult to separate the effects of chronic GVHD on osteo-
blasts from those of treatment with steroids, as steroids also
decrease osteoblastic proliferation and activity [22]. We
observed a higher frequency of GVHD treatment with ste-
roids in patients who had idiopathic cytopenias with osteo-
blast loss (Table 4), indicating more severe systemic GVHD
with BM GVHD that required steroid therapy.
In conclusion, we have shown for the ﬁrst time, to our
knowledge, the direct proof of BM GVHD and the loss of
osteoblasts in chronic GVHD patients. Further studies with a
large number of patients are warranted; however, our ﬁnd-
ings explain the cause of idiopathic cytopenias after allo-
HSCT and give valuable insights for clinicians to use in
treating patients suffering from BM suppression after allo-
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